Stay updated with breaking news from Renalys Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
FDA grants Priority Review for sNDA to convert FILSPARI® from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 Received 511...
15.02.2024 - Received 459 new patient start forms (PSFs) for FILSPARI (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023 Company nearing submission of sNDA to convert U.S. accelerated approval of FILSPARI in IgAN to full approval ...
Renalys plans to start a registrational trial for sparsentan as a treatment for IgA nephropathy in Japan in Q2 2024.
/PRNewswire/ -- Catalys Pacific, a transpacific life science investment firm, and SR One, a transatlantic life sciences investment firm, today announced the...
Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA nephropathy in JapanSAN DIEGO, Jan. 25, 2024 -- Travere...